HCA Healthcare price target raised to $345 from $330 at Oppenheimer

Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on HCA Healthcare to $345 from $330 and keeps an Outperform rating on the shares. HCA produced strong Q1 2024 results, driven by continued traction with cost management efforts and robust top-line trends, the firm says. Underlying these results, management noted that Medicaid was weaker, while commercial was stronger due to Medicaid redeterminations. Despite the beat, HCA maintained FY2024 guidance, Oppenheimer adds.